Transgenic expression of tpr-met oncogene leads to development of mammary hyperplasia and tumors

Journal of Clinical Investigation

Volumn 97, Issue 12, 1996, Pages 2872-2877

  Liang, T Jake ^a,c   Reid, Andrea E ^a   Xavier, Ramnik ^a   Cardiff, Robert D ^b   Wang, Timothy C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

c met; carcinogenesis; hepatocyte growth factor; receptor tyrosine kinase; sarcoma

Indexed keywords

PROTEIN TYROSINE KINASE; SCATTER FACTOR;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST HYPERPLASIA; BREAST TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MALE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 0029889439     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118744     Document Type: Article

References (26)

1. Bottaro, D.P., J.S. Rubin, D.L. Faletto, A.M.-L. Chan, T.E. Kmiecik, G. Vande Woude, and S.A. Aaronson. 1991. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (Wash. DC). 251:802-804.
2. Weidner, K.M., J. Behrens, J. Vandekerckhove, and W. Birchmeier. 1990. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol. 111:2097-2108.
3. Gherardi, E., and M. Stoker. 1991. Hepatocyte growth factor-scatter factor: mitogen, motogen, and met. Cancer Cells. 3:227-232.
4. Faletto, D.L., D.R. Kaplan, D.O. Halverson, E.M. Rosen, and G.F. Vande Woude. 1993. Hepatocyte Growth Factor-Scatter Factor and the c-met Receptor. I.E. Goldberg and E.M. Rosen, editors. 107-130.
5. Montesano, R., K. Matsumoto, T. Nakamura, and L. Orci. 1991. Identification of fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell. 67:901-908.
6. Nakamura, T. 1992. Structure and function of hepatocyte growth factor. Prog. Growth Factor Res. 3:67-86.
7. Rong, S., S. Segal, M. Anver, J.H. Resau, and G.F. Vande Woude. 1994. Invasiveness and metastasis of NIH 3T3 cells induced by met-hepalocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA. 91:4731-4735.
8. Park, M., M. Dean, C.S. Cooper, M. Schmidt, J. O'Brien, D.G. Blair, and G.V. Woude. 1986. Mechanism of met oncogene activation. Cell 45:895-904.
9. Chan, A.M.-L., H.W.S. King, P.R. Tempest, E.A. Deakin, C.S. Cooper, and P. Brookes. 1987. Primary structure of the met protein tyrosine kinase domain. Oncogene. 1:229-233.
10. Park, M., M. Dean, K. Kaul, M. J. Braun, M.A. Gonda, and G.V. Woude. 1987. Sequence of met protooncogene cDNA has features characteristic of the tyrosine kinase family of growth-factor receptors. Proc. Natl. Acad. Sci. USA. 84:6379-6383.
11. Capelanaki, Y., I. Kuisk, K. Rothblum, and S. Starnes. 1990. Mouse vimentin: structural relationship to fos, jun, CREB, and tpr. Oncogene. 5:645-655.
12. Landschulz, W.H., P.F. Johnson, and S.L. McKnight. 1988. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science (Wash. DC). 240:1759-1764.
13. Rodrigues, G., and M. Park. 1993. Dimerization mediated through a Leucine zipper activates the oncogenic potential of the met receptor tyrosine kinase. Mol. Cell. Biol. 13:6711-6722.
14. Comoglio, P.M. 1993. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. In Hepatocyte Growth Factor-Scatter Factor and the c-met Receptor. I.E. Goldberg and E.M. Rosen, editors. 131-165.
15. Renzo, M.F., R.P. Narsimhan, and M. Olivero. 1991. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene. 6:1997-2003.
16. Rong, S., M. Jeffers, J. Resau, I. Tsarfaty, M. Oskarsson, and G.F. Vande Woude. 1993. Met expression and sarcoma tumorigenicity. Cancer Res. 53:5355-5360.
17. Bargmann, C.I., C. Hung, and R.A. Weinberg. 1986. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell. 45:649-657.
18. Roussel, M.F., J.R. Downing, C.W. Rettenmier, and C.J. Sherr. 1988. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell. 55:979-988.
19. Woolkord, J.W., A. McAuliffe, and L.R. Rohrschneider. 1988. Activation of the feline v-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell. 55:965-967.
20. Low, M.J., R.E. Hammer, R.H. Goodman, J.F. Habener, R.D. Palmiter, and R.L. Brinster. 1985. Tissue-specific posttranslational processing of preprosomatostatin encoded by a metallothionein-somatostatin fusion gene in transgenic mice. Cell. 41:211-219.
21. Cardiff, R.D., E. Sinn, W. Muller, and P. Leder. 1991. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am. J. Pathol. 139:495-501.
22. Huang, M.T.F., and C.M. Gorman. 1990. The simian virus 40 small-t intron, present in many common expression vectors, leads to aberrant splicing. Mol. Cell Biol. 10:1805.
23. Wang, T.C., R.D. Cardiff, L. Zukerberg, E. Lees, A. Arnold, and E.V. Schmidt. 1994. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature (Lond.). 369:669-671.
24. Grigioni, W.F., M. Fiorentino, A. D'Errico, A. Ponzetto, T. Crepaldi, M. Prat, and P.M. Comoglio. 1995. Overexpression of c-met protooncogene product and raised Ki67 index in hepatocellular carcinomas with respect to benign liver conditions. Hepatology. 21:1543-1546.
25. Bieche, I., M.H. Champreme, F. Matifas, K. Hacene, R. Callanhan, and R. Lidereau. 1992. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet. 339:139-143.
26. Tsarfaty, I., J.H. Resau, S. Rulong, I. Keydar, D.L. Faletto, and G.F. Vande Woude. 1992. The met proto-oncogene receptor and lumen formation. Science (Wash. DC). 257:1258-1261.